SK287355B6 - Kryštálové formy fenyletanolamínu, spôsob ich prípravy a farmaceutické kompozície, ktoré ich obsahujú - Google Patents

Kryštálové formy fenyletanolamínu, spôsob ich prípravy a farmaceutické kompozície, ktoré ich obsahujú Download PDF

Info

Publication number: SK287355B6
Authority: SK; Slovakia
Prior art keywords: chlorophenyl; hydroxyethylamino; yloxy; ethyl; tetrahydronaphth
Prior art date: 2001-06-28

Application number

SK1593-2003A

Other languages

English (en)

Slovak (sk)

Other versions

SK15932003A3 (sk

Inventor

Antoine Caron

Olivier Monnier

Sabrina Obert

J�Rome Roche

Isabelle Ziri

Original Assignee

Sanofi - Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-28

Filing date

2002-06-27

Publication date

2010-08-09

2002-06-27 Application filed by Sanofi - Aventis filed Critical Sanofi - Aventis

2004-05-04 Publication of SK15932003A3 publication Critical patent/SK15932003A3/sk

2010-08-09 Publication of SK287355B6 publication Critical patent/SK287355B6/sk

Links

238000002360 preparation method Methods 0.000 title claims description 10
239000008194 pharmaceutical composition Substances 0.000 title claims description 4
ULSIYEODSMZIPX-UHFFFAOYSA-N phenylethanolamine Chemical class NCC(O)C1=CC=CC=C1 ULSIYEODSMZIPX-UHFFFAOYSA-N 0.000 title 2
229950006768 phenylethanolamine Drugs 0.000 title 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 5
238000010521 absorption reaction Methods 0.000 claims abstract description 5
238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 5
239000003814 drug Substances 0.000 claims abstract description 3
150000001875 compounds Chemical class 0.000 claims description 21
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 20
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 16
238000000034 method Methods 0.000 claims description 11
125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 9
239000000725 suspension Substances 0.000 claims description 9
BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims description 8
238000002425 crystallisation Methods 0.000 claims description 7
230000008025 crystallization Effects 0.000 claims description 7
238000002329 infrared spectrum Methods 0.000 claims description 7
239000002904 solvent Substances 0.000 claims description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 5
239000013078 crystal Substances 0.000 claims description 5
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 4
HDRXZJPWHTXQRI-BHDTVMLSSA-N diltiazem hydrochloride Chemical group [Cl-].C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CC[NH+](C)C)C2=CC=CC=C2S1 HDRXZJPWHTXQRI-BHDTVMLSSA-N 0.000 claims description 4
238000010899 nucleation Methods 0.000 claims description 4
238000004821 distillation Methods 0.000 claims description 3
238000003756 stirring Methods 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims description 2
238000000113 differential scanning calorimetry Methods 0.000 claims description 2
238000001704 evaporation Methods 0.000 claims description 2
230000008020 evaporation Effects 0.000 claims description 2
150000002576 ketones Chemical class 0.000 claims description 2
239000003960 organic solvent Substances 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims 1
230000008018 melting Effects 0.000 abstract description 6
238000002844 melting Methods 0.000 abstract description 6
238000001953 recrystallisation Methods 0.000 abstract description 3
241001529856 Celsia Species 0.000 abstract 1
IRAVYHIRJICKRS-UHFFFAOYSA-N acetic acid;hypochlorous acid Chemical compound ClO.CC(O)=O IRAVYHIRJICKRS-UHFFFAOYSA-N 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
NQIZCDQCNYCVAS-RQBPZYBGSA-N ethyl 2-[[(7s)-7-[[(2r)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]acetate;hydron;chloride Chemical compound Cl.C1([C@@H](O)CN[C@H]2CCC3=CC=C(C=C3C2)OCC(=O)OCC)=CC=CC(Cl)=C1 NQIZCDQCNYCVAS-RQBPZYBGSA-N 0.000 description 20
239000000203 mixture Substances 0.000 description 12
239000000047 product Substances 0.000 description 8
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
238000001035 drying Methods 0.000 description 6
238000001816 cooling Methods 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
238000002441 X-ray diffraction Methods 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
IWULAYUMJUBQMC-RXVVDRJESA-N [(7S)-7-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-1-ethyl-5,6,7,8-tetrahydronaphthalen-2-yl] ethaneperoxoate Chemical compound CCc1c(OOC(C)=O)ccc2CC[C@@H](Cc12)NC[C@H](O)c1cccc(Cl)c1 IWULAYUMJUBQMC-RXVVDRJESA-N 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
239000008240 homogeneous mixture Substances 0.000 description 2
239000003999 initiator Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
238000009835 boiling Methods 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000008298 dragée Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000012065 filter cake Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000008991 intestinal motility Effects 0.000 description 1
229960001021 lactose monohydrate Drugs 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
230000006911 nucleation Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000007940 sugar coated tablet Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SK1593-2003A 2001-06-28 2002-06-27 Kryštálové formy fenyletanolamínu, spôsob ich prípravy a farmaceutické kompozície, ktoré ich obsahujú SK287355B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0108562A FR2826651B1 (fr)	2001-06-28	2001-06-28	Forme cristalline d'une phenylethanolamine, sa preparation et compositions pharmaceutiques la contenant
PCT/FR2002/002235 WO2003002510A1 (fr)	2001-06-28	2002-06-27	Forme cristalline d'une phenylethanolamine, sa preparation et compositions pharmaceutiques la contenant

Publications (2)

Publication Number	Publication Date
SK15932003A3 SK15932003A3 (sk)	2004-05-04
SK287355B6 true SK287355B6 (sk)	2010-08-09

Family

ID=8864888

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1593-2003A SK287355B6 (sk)	2001-06-28	2002-06-27	Kryštálové formy fenyletanolamínu, spôsob ich prípravy a farmaceutické kompozície, ktoré ich obsahujú

Country Status (29)

Country	Link
US (1)	US6992211B2 (de)
EP (1)	EP1404641B1 (de)
JP (2)	JP4171413B2 (de)
KR (1)	KR100869017B1 (de)
CN (1)	CN1269797C (de)
AR (1)	AR034648A1 (de)
AT (1)	ATE403642T1 (de)
AU (1)	AU2002333942B2 (de)
BR (1)	BR0210661A (de)
CA (1)	CA2450213C (de)
CY (1)	CY1110099T1 (de)
CZ (1)	CZ301450B6 (de)
DE (1)	DE60228088D1 (de)
DK (1)	DK1404641T3 (de)
EE (1)	EE05380B1 (de)
ES (1)	ES2307798T3 (de)
FR (1)	FR2826651B1 (de)
HU (1)	HUP0401229A3 (de)
IL (2)	IL159134A0 (de)
MX (1)	MXPA03011742A (de)
NO (1)	NO331169B1 (de)
NZ (1)	NZ530140A (de)
PL (1)	PL206680B1 (de)
PT (1)	PT1404641E (de)
SI (1)	SI1404641T1 (de)
SK (1)	SK287355B6 (de)
TW (1)	TWI286129B (de)
WO (1)	WO2003002510A1 (de)
ZA (1)	ZA200309512B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2826651B1 (fr) *	2001-06-28	2005-09-02	Sanofi Synthelabo	Forme cristalline d'une phenylethanolamine, sa preparation et compositions pharmaceutiques la contenant
EP1623705A1 (de) *	2004-07-09	2006-02-08	Sanofi-Aventis	Verwendung von Phenyläthanolaminotetralinen zur Herstellung von Anxiolytika
FR2890862B1 (fr) *	2005-09-19	2008-01-25	Sanofi Aventis Sa	Association d'agoniste aux recepteurs beta 3 et d'inhibiteur de la recapture de monoamnies, compostion pharmaceutique la contenant et son utilisation en therapeutique.
EP3397765B1 (de)	2015-12-30	2023-02-01	Bio-Rad Laboratories, Inc.	Verfahren zur quantifizierung von wildtyp- und mutanten-fragmenten in einer nukleinsäureprobe

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0303546B1 (de) *	1987-08-12	1994-12-28	Sanofi	Verfahren zur O-Alkylierung von N-(Hydroxy)aralkylphenylethanolamin
US5198586A (en) *	1987-08-12	1993-03-30	Sanofi	Process for the preparation of phenylethanolaminotetralins
US5235103A (en) *	1987-08-12	1993-08-10	Sanofi	Process for the preparation of phenylethanolaminotetralins
US5202466A (en) *	1988-06-14	1993-04-13	Sanofi	2-amino-7-hydroxytetraline ethers
FR2648042B1 (fr) *	1989-06-13	1994-06-10	Midy Spa	Utilisation de phenylethanolaminotetralines pour la preparation de medicaments pour le traitement des affections oculaires
US5312961A (en) *	1989-02-14	1994-05-17	Elf Sanofi	2-amino-7-hydroxytetralin carboxylalkyl ethers
FR2643076B1 (fr) *	1989-02-14	1991-06-21	Midy Spa	Carboxyalkyl-ethers de la 2-amino-7-hydroxytetraline
FR2669821A1 (fr) *	1990-12-04	1992-06-05	Sanofi Sa	Utilisation de phenylethanolaminotetralines pour la preparation de medicaments destines au traitement de la depression.
FR2826651B1 (fr) *	2001-06-28	2005-09-02	Sanofi Synthelabo	Forme cristalline d'une phenylethanolamine, sa preparation et compositions pharmaceutiques la contenant

2001
- 2001-06-28 FR FR0108562A patent/FR2826651B1/fr not_active Expired - Fee Related
2002
- 2002-06-27 EP EP02780917A patent/EP1404641B1/de not_active Expired - Lifetime
- 2002-06-27 AR ARP020102421A patent/AR034648A1/es active IP Right Grant
- 2002-06-27 SK SK1593-2003A patent/SK287355B6/sk not_active IP Right Cessation
- 2002-06-27 DE DE60228088T patent/DE60228088D1/de not_active Expired - Lifetime
- 2002-06-27 AU AU2002333942A patent/AU2002333942B2/en not_active Ceased
- 2002-06-27 DK DK02780917T patent/DK1404641T3/da active
- 2002-06-27 PL PL368055A patent/PL206680B1/pl not_active IP Right Cessation
- 2002-06-27 PT PT02780917T patent/PT1404641E/pt unknown
- 2002-06-27 HU HU0401229A patent/HUP0401229A3/hu unknown
- 2002-06-27 SI SI200230728T patent/SI1404641T1/sl unknown
- 2002-06-27 CZ CZ20033531A patent/CZ301450B6/cs not_active IP Right Cessation
- 2002-06-27 AT AT02780917T patent/ATE403642T1/de active
- 2002-06-27 US US10/480,427 patent/US6992211B2/en not_active Expired - Fee Related
- 2002-06-27 EE EEP200400007A patent/EE05380B1/xx not_active IP Right Cessation
- 2002-06-27 JP JP2003508694A patent/JP4171413B2/ja not_active Expired - Fee Related
- 2002-06-27 NZ NZ530140A patent/NZ530140A/en not_active IP Right Cessation
- 2002-06-27 ES ES02780917T patent/ES2307798T3/es not_active Expired - Lifetime
- 2002-06-27 TW TW091114166A patent/TWI286129B/zh not_active IP Right Cessation
- 2002-06-27 BR BR0210661-2A patent/BR0210661A/pt not_active Application Discontinuation
- 2002-06-27 KR KR1020037016946A patent/KR100869017B1/ko not_active Expired - Fee Related
- 2002-06-27 WO PCT/FR2002/002235 patent/WO2003002510A1/fr not_active Ceased
- 2002-06-27 MX MXPA03011742A patent/MXPA03011742A/es active IP Right Grant
- 2002-06-27 CA CA2450213A patent/CA2450213C/en not_active Expired - Fee Related
- 2002-06-27 CN CNB028130952A patent/CN1269797C/zh not_active Expired - Fee Related
- 2002-06-27 IL IL15913402A patent/IL159134A0/xx unknown
2003
- 2003-11-30 IL IL159134A patent/IL159134A/en not_active IP Right Cessation
- 2003-12-08 ZA ZA200309512A patent/ZA200309512B/xx unknown
- 2003-12-29 NO NO20035839A patent/NO331169B1/no not_active IP Right Cessation
2008
- 2008-07-08 JP JP2008178049A patent/JP4799592B2/ja not_active Expired - Fee Related
- 2008-09-24 CY CY20081101044T patent/CY1110099T1/el unknown

Also Published As

Publication number	Publication date
CY1110099T1 (el)	2015-01-14
US20040180953A1 (en)	2004-09-16
HUP0401229A3 (en)	2008-03-28
BR0210661A (pt)	2004-10-05
HK1063621A1 (zh)	2005-01-07
CA2450213A1 (en)	2003-01-09
PL368055A1 (en)	2005-03-21
EE05380B1 (et)	2011-02-15
AU2002333942B2 (en)	2008-02-28
CN1269797C (zh)	2006-08-16
CN1522241A (zh)	2004-08-18
FR2826651B1 (fr)	2005-09-02
WO2003002510A1 (fr)	2003-01-09
TWI286129B (en)	2007-09-01
ES2307798T3 (es)	2008-12-01
EE200400007A (et)	2004-02-16
PL206680B1 (pl)	2010-09-30
CZ301450B6 (cs)	2010-03-03
JP4171413B2 (ja)	2008-10-22
FR2826651A1 (fr)	2003-01-03
CZ20033531A3 (en)	2004-04-14
JP2009029804A (ja)	2009-02-12
HUP0401229A2 (hu)	2004-10-28
ZA200309512B (en)	2004-12-08
DK1404641T3 (da)	2008-12-08
NO20035839L (no)	2004-03-01
NO331169B1 (no)	2011-10-24
ATE403642T1 (de)	2008-08-15
MXPA03011742A (es)	2004-07-01
SI1404641T1 (sl)	2008-10-31
EP1404641B1 (de)	2008-08-06
US6992211B2 (en)	2006-01-31
SK15932003A3 (sk)	2004-05-04
CA2450213C (en)	2011-02-15
IL159134A0 (en)	2004-05-12
DE60228088D1 (de)	2008-09-18
NZ530140A (en)	2005-05-27
IL159134A (en)	2009-07-20
AR034648A1 (es)	2004-03-03
JP2004530725A (ja)	2004-10-07
EP1404641A1 (de)	2004-04-07
KR100869017B1 (ko)	2008-11-17
KR20040017817A (ko)	2004-02-27
JP4799592B2 (ja)	2011-10-26
PT1404641E (pt)	2008-09-22

Legal Events

Date	Code	Title	Description
2013-03-01	MM4A	Patent lapsed due to non-payment of maintenance fees	Effective date: 20120627

Publication	Publication Date	Title
JP5086069B2 (ja)	2012-11-28	重硫酸アタザナビルおよび新規形態の製造方法
US20020035130A1 (en)	2002-03-21	Novel compound
NO320047B1 (no)	2005-10-17	Sammensetning for oral administrering
SK8332002A3 (en)	2003-04-01	Novel processes for making- and a new crystalline form of leflunomide
JP4799592B2 (ja)	2011-10-26	フェニルエタノールアミンの結晶形の製造方法
US9593117B2 (en)	2017-03-14	Crystalline form of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
US9593116B2 (en)	2017-03-14	Crystalline forms of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
US9464086B2 (en)	2016-10-11	Crystalline forms of N,N-dicyclopropyl-4-(1,5-dimethyl-1 H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-D]pyrrolo[2,3-B]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
KR100536750B1 (ko)	2005-12-16	시부트라민 메탄술폰산염의 결정성 반수화물을 포함하는약학 조성물
US9598413B2 (en)	2017-03-21	Crystalline form of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-D]pyrrolo[2,3-B]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
CN105461569B (zh)	2017-06-06	一种枸橼酸阿尔维林新晶型及其制备方法
EP1674468A1 (de)	2006-06-28	Polymorphe von Clopidogrel Hydrobromid
HK1063621B (en)	2009-04-24	Crystalline form of a phenylethanolamine, the preparation thereof and pharmaceutical compositions comprising the same
HK1174608A (en)	2013-06-14	Novel polymorphs and salts
CZ20004924A3 (cs)	2001-06-13	Methansulfonat paroxetinu